NEW YORK, March 21, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Sempra Energy (“Sempra Energy” or the “Company”) (NYSE:SRE) between May 14, 2015 and November 23, 2015.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of California. If you purchased or otherwise acquired Sempra Energy securities between May 14, 2015 and November 23, 2015, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/sempra-energy.
The complaint alleges that throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Sempra’s subsidiary SoCalGas lacked the capability to expeditiously repair gas leaks, causing a public hazard; (2) an extended hazardous gas leak would constitute a serious threat to public health and safety; and (3) as a result, Sempra’s public statements were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you suffered a loss in Sempra Energy you have until May 2, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/sempra-energy.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.